B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial.
BACKGROUND
In observational studies, hyperhomocysteinemia has been found to be a risk factor for total mortality and cardiovascular events in patients with end-stage renal disease. These patients have grossly elevated homocysteine levels that can be lowered by supplementation with folic acid and vitamin B(12). We conducted a randomized clinical trial with B vitamins to reduce homocysteine levels and therefore cardiovascular events and total mortality.


RESULTS
This randomized, double-blind multicenter study was conducted in 33 dialysis centers in north and east Germany between July 2002 and July 2008. We randomly assigned 650 patients with end-stage renal disease who were undergoing hemodialysis to 2 postdialysis treatments: 5 mg folic acid, 50 microg vitamin B(12), and 20 mg vitamin B(6) (active treatment) or 0.2 mg folic acid, 4 microg vitamin B(12), and 1.0 mg vitamin B(6) (placebo) given 3 times per week for an average of 2 years. The primary outcome was total mortality; the secondary outcome was fatal and nonfatal cardiovascular events. The primary outcome occurred in 102 patients (31%) receiving the active treatment and in 92 (28%) receiving placebo (hazard ratio, 1.13; 95% confidence interval, 0.85 to 1.50; P=0.51). The secondary outcome occurred in 83 patients (25%) receiving the active treatment and in 98 (30%) receiving placebo (hazard ratio, 0.80; 95% confidence interval, 0.60 to 1.07; P=0.13).


CONCLUSIONS
Increased intake of folic acid, vitamin B(12), and vitamin B(6) did not reduce total mortality and had no significant effect on the risk of cardiovascular events in patients with end-stage renal disease. Clinical Trial Registration- URL: www.anzctr.org.au. Unique identifier: ACTRN12609000911291. URL: www.cochrane-renal.org. Unique identifier: CRG010600027.
Heinz
Judith
J
Institute of Clinical Chemistry, Magdeburg University Hospital, Magdeburg, Germany. j.heinz@uke.de
Kropf
Siegfried
S
Domröse
Ute
U
Westphal
Sabine
S
Borucki
Katrin
K
Luley
Claus
C
Neumann
Klaus H
KH
Dierkes
Jutta
J
D000368:Aged; D002318:Cardiovascular Diseases / Q000209:etiology*; D004311:Double-Blind Method; D005260:Female; D006710:Homocysteine / Q000097:blood / Q000187:drug effects; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009026:Mortality; D006435:Renal Dialysis; D012306:Risk; D017211:Treatment Failure; D016896:Treatment Outcome; D014803:Vitamin B Complex / Q000008:administration & dosage* / Q000627:therapeutic use
D006710:Homocysteine; D014803:Vitamin B Complex